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Abstract: Seasonal allergic rhinitis (SAR) is increasing in prevalence such that 1 in 4   persons 
is affected in the UK. It represents a considerable burden of disease since in a significant 
proportion of individuals the severity of nasal–ocular symptoms has an important effect on 
daily activity, performance and quality of life. Intranasal steroids (INS) form the mainstay of 
treatment, having been shown in meta-analyses to be superior to oral antihistamines,   intranasal 
antihistamines and anti-leukotrienes. Fluticasone propionate is an established INS for the 
  treatment of rhinitis, including SAR. Its favorable pharmacological profile combining high 
local efficacy with low systemic bioavailability has established fluticasone propionate as an 
effective intervention. The more recent introduction of structurally related fluticasone furoate 
with similar but enhanced pharmacological characteristics with a novel delivery device may 
confer further therapeutic advantages.
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Seasonal allergic rhinitis
Allergic rhinitis is a highly prevalent chronic condition, which presents an e  normous 
global health burden. It is estimated that at least 500 million individuals have   allergic 
rhinitis (AR) and it is one of the most common reasons for attendance with a   primary 
care practitioner.1 The nasal manifestations of AR are congestion,   rhinorrhea, 
  itching and sneezing. Ocular symptoms occur in at around 70% of individuals with 
seasonal allergic rhinitis (SAR), so it is more appropriate to use the term allergic 
  rhinoconjunctivitis. The ocular manifestations are watery eyes, itching, burning 
(  irritability), redness and injection of the conjunctiva and sometimes periorbital edema. 
In Europe, 71% of patients experience both nose and eye symptoms and up to 33% 
of these are moderate or severe.2
The relationship between nasal-ocular symptoms and seasonal allergen exposure 
plus demonstration of IgE-specific sensitization is diagnostic of SAR.
Seasonal allergic rhinitis (SAR) or hay fever (termed ‘spring catarrh’ back in the 
19th century) has rapidly increased in prevalence in the last 50 years, particularly in 
the developed world.3–5 A recent multi-center study involving 33 centers in Europe 
demonstrated sensitization to grass pollen (predominantly timothy grass) with a median 
prevalence of 16.9%, just behind sensitization to house dust mite (Dermatophagoides 
pteronyssinus) at 21.7%.6
Rhinitis is also defined in the ‘allergic rhinitis and its impact in asthma’ (ARIA) 
document in terms of the duration of symptoms (ie, intermittent versus persistent) 
and effects on quality of life (QOL), thus aiding treatment decisions.1 However, given  Journal of Asthma and Allergy  2010: 3 submit your manuscript | www.dovepress.com
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the spectrum of respiratory disease that can present with 
rhinitis symptoms7 and the possible use of allergen specific 
  immunotherapy, retention of the key term seasonality is very 
useful in the diagnostic algorithm and has been retained by 
several guidelines and standards of care documents.8
Mechanisms of allergic rhinitis
The basic concepts that underlie allergic inflammation 
are o  utlined. Antigen presenting cells (APC) take up 
allergen, which has reached the nasal mucosa. Dendritic 
cells in   particular present processed allergen peptides in 
the context of MHC Class II to naïve and antigen-specific 
memory T cells, leading to a Th2 polarized response in 
atopic i  ndividuals. Allergen specific IgE is tightly held 
on the surface of resident mast cells that express the high 
affinity (FcεRI) IgE receptor. This is allergen s  ensitization. 
Subsequent allergen   impaction on the nasal mucosal surface 
leads to s  olubilization and   diffusion across to sites of mast 
cell (MC) residence.   Cross-linking of two or more affinity 
IgE   molecules in response to allergen binding leads to MC 
activation, degranulation, and release of mediators such 
as histamine, leukotrienes and ne  uropeptides, in  itiating an 
inflammatory signaling cascade. Rapid neuronal activation 
and vascular leakage are manifest by almost instantaneous 
sneezing, nasal itch and congestion. Release of pre-formed 
key cytokines such as interleukin (IL)-13 contribute to 
mucus hypersecretion and together with IL-5 and IL-4 drive 
further cellular recruitment and sustain the   inflammatory 
response. Intense cellular infiltration is associated with 
  further priming of the upper airway innate and adaptive 
immune responses along with structural cell activation 
(epithelium and s  ubmucosal fibroblasts) and enhanced local 
IgE   production.9 This leads to a primed and rapid immune 
response on f  urther allergen exposure that contributes to 
the severity and   chronicity of symptoms. Ocular symptoms 
can be   particularly t  roublesome in SAR.10 Whilst some of 
these relate to direct allergen   impaction on the eye with local 
mast cell d  egranulation and initiation of immune signaling 
cascades, deposition of   allergen in the nasal mucosa alone 
can   activate ocular responses termed the ‘the naso-ocular 
reflex’.11 Steroids attenuate key aspects of this   allergen-induced 
inflammatory process. The clinical t  ranslation is effective 
therapeutic intervention.
Treatment of allergic rhinitis
Oral and intranasal antihistamines, mast cell st  abilizers, 
leukotriene inhibitors, decongestants and intranasal 
a  nticholinergics, in addition to intranasal steroids, are all 
established evidence-based therapeutic interventions for AR.1 
They are not equally effective12 and INS on meta-  analyses 
are significantly more effective than oral or i  ntranasal 
a  ntihistamines and anti-leukotrienes and equal to the 
  combination of anti-histamine plus anti-leukotriene.13–15
For mild disease either a second-generation antihistamine 
or topical nasal corticosteroid (INS) is recommended.1,16 For 
moderate to severe disease or when nasal congestion is pre-
dominant, INS are first line treatment.17,8 For the majority of 
patients with allergic rhinoconjunctivitis, intranasal steroids 
remain the most effective treatment since all of the major 
symptoms associated with AR are effectively attenuated.
An important aspect is the effect of upper airway 
  inflammation on lower airway symptoms. It is often not 
  recognized by the respiratory community that up to 80% 
individuals with asthma have rhinitis.18 SAR is   commonly 
  associated with seasonal allergic asthma, and with 
  demonstrable increases in airway hyper-responsiveness 
(AHR) that can translate into asthma exacerbation.19 
  Intranasal steroids alone can prevent this seasonal increase 
in AHR and symptoms.20 Intranasal steroid can be more 
  effective in this respect than inhaled corticosteroids.21,22
Efficacy and compliance
For any drug to have significant impact upon a disease, it 
must demonstrate clinical efficacy, an excellent safety profile 
and must be used appropriately. Minimal dosing frequency 
and ease of delivery device will promote compliance with 
therapy. Important pharmacological characteristics for a 
topical steroid are a high affinity for the target tissue and 
steroid receptor with subsequent slow dissociation, ensuring 
maximal and prolonged local tissue effects. This will also 
decrease potential systemic effects by delayed release from 
target tissue. Given that more than 80% of any nasal steroid is 
swallowed, a molecule that is either minimally absorbed from 
the gastrointestinal tract and/or undergoes maximal hepatic 
first-pass metabolism will substantially decrease   systemic 
bioavailability. The development of intranasal steroids is 
one of the best examples of molecular modification of a 
compound to achieve the best therapeutic index.
The emergence  
of intranasal steroids
The steroid compounds cortisol and cortisone were first 
identified from the adrenal cortex in the late 1930s.23 With 
the realization that these were potent anti-inflammatory 
agents,24 methods of producing large amounts of synthetic 
cortisone were sought. However, it became evident that  Journal of Asthma and Allergy  2010: 3 submit your manuscript | www.dovepress.com
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both cortisone and cortisol induced clinically significant 
adverse effects such as severe electrolyte disturbances that 
limited the dose and duration of use. The development of 
compounds that utilized the anti-inflammatory potency of 
cortisone without the systemic effects was urgently required. 
Structure – activity relationship to absorption, distribution, 
metabolism and elimination of steroid compounds could be 
demonstrated. Functional modification of the steroid structure 
generated compounds with increased activity and improved 
safety profile.25
Target-specific delivery is still the most effective strategy 
to minimalize systemic effects of any drug, yet it was not 
until the early 1970s that attempts to deliver airway-specific 
steroid in the form of beclomethasone dipropionate (BDP) 
for asthma were undertaken.26 The first intranasal delivery 
of BDP for SAR was in 197327 and BDP remains the most 
clinically used steroid formulation. Seven further licensed 
intranasal preparations are currently available: flunisolide 
(since 1976),28 budesonide since the early 1980s,29   fluticasone 
propionate (FP) and triamcinolone acetonide since the early 
1990s.30,31 Trials with ciclesonide were first published in 
1999 and mometasone furoate since1996.32,33 Fluticasone 
furoate (FF) was launched in 2009. Each corticosteroid is 
defined by a specific pharmacokinetic and pharmacodynamic 
profile. The early market entry of FP with the demonstration 
of high clinical efficacy and negligible oral bioavailability 
established it as a key therapeutic intervention in AR and 
asthma. Fluticasone furoate (FF) is an evolution of FP and 
there are reports of therapeutic advantages over FP.
Structure–activity relationship
Cortisol is a natural steroid with potent glucocorticoid and 
mineralocorticoid action. Four carbon rings (3 rings with 
6 carbons and 1 ring with only 5 carbons define the structure) 
(Figure 1A). In addition there is a 11β-hyroxyl group that 
is essential for the glucocorticoid and anti-inflammatory 
effect of the molecule. All corticosteroids maintain this core 
structure and the 4,5-carbon unsaturated double bond and 
the 3-carbon position keto-group are considered essential 
for bioactivity (Figure 1A). Manipulation of the structural 
attachments in the 5-carbon ring has allowed manufacture 
of synthetic corticosteroids with characteristic profiles. The 
addition of a double bond to the 1,2-carbon position of the first 
ring increased glucocorticoid potency and decreased metabo-
lism (Figure 1B). The introduction of   halogenation at specific 
points of the molecule increased both the   glucocorticoid and 
mineralocorticoid effects.34 FP is   halogenated at both the 6α 
and the 9α position.35   Adding a methyl group to the 16-carbon 
position abolished   mineralocorticoid activity. Topical potency 
was increased by adding an esterified lipophilic group to the 
5-carbon ring (17α) position.36,37 Such halogenation was asso-
ciated with an almost 7-fold increase in binding affinity for 
the   glucocorticoid receptor.38 Lipophilicity of the compound 
is correlated with tissue absorption and retention.37
Mechanism of action of steroids  
in airway inflammation
Glucocorticoids work by penetrating the plasma membrane 
of the cell and by binding to the cytosolic glucocorticoid 
receptor (GR). In humans a single GR gene transcribes 
two separate receptors GR-alpha (α) and GR-beta (β). 
GR-α is ubiquitously expressed and is considered the key 
GR in anti-inflammatory responses. Upon GR binding, the 
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Figure 1 Structure of cortisol with the nomenclature of the steroid molecule 
outlined (1A). The structure of fluticasone propionate (FP) (1B) and fluticasone 
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GC-GR   complex translocates into the nucleus.   Repression 
of   inflammatory gene activation is achieved through several 
heterogeneous mechanisms. The GC-GR complex binds 
DNA at the glucocorticoid response elements (GRE) in 
the 5′-upstream region of the steroid responsive genes. 
  Transcriptional activation of anti-inflammatory genes or 
repression of pro-inflammatory ones can now occur. Other 
mechanisms of regulating inflammation are via protein –   
  protein sequestration via binding to other pro-inflammatory 
transcription factors such as activator protein (AP-1), leading 
to the inhibition of the transcription of inflammatory genes. 
The GC-GR complex can also act indirectly via the   induction 
of inhibitory proteins, for example IκB that suppresses 
NF-κB activity.39 Although GR-β expression has been 
demonstrated in asthma and nasal polyposis, particularly in 
relation to inflammatory cells, its role remains uncertain.
Fluticasone propionate
Fluticasone propionate is a topically active corticosteroid 
with established efficacy in seasonal and perennial AR. The 
excellent pharmacodynamic and pharmacokinetic properties 
along with safety have given FP a key position as one of the 
market leaders. This impressive therapeutic and safety profile 
is a reflection of its rapid and extensive uptake by airway 
tissue, marked affinity for the GR and almost undetectable 
systemic bioavailability.40
The propionate ester side chain renders FP highly 
  lipophilic. Such lipophilicity is a key determinant of 
its   pharmacological profile and allows the drug to bind 
t  issue rapidly and strongly with more prolonged reten-
tion than more hydrophilic molecules such as budesonide 
and   hydrocortisone.41 Potency and hence therapeutic 
efficacy is further determined by the GR binding affin-
ity. The greater the steroid – receptor affinity the longer 
is the   binding time and hence transcriptional regulation 
of genes and protein   interactions. Binding studies using 
  competition assays and in vitro binding kinetic studies have 
confirmed the high s  electivity and affinity of FP for the GR 
  receptor. FP   demonstrates a high association rate constant 
and a   pronounced low dissociation constant predicting an 
  equilibrium dissociation constant (Kd) (ie, the propensity 
of the GC-GR complex to dissociate) of 0.49/0.51 nmol/L 
compared to the Kd of dexamethasone at 9.36/8.80 nmol/L. 
The relative receptor affinity (RRA) of FP to the human GR 
(compared relative to dexamethasone with an RRA of 100) 
is 1910/1775.41,42 These data are summarized in Table 1. Such 
a fast association, high receptor affinity and subsequent low 
dissociation predicts clinical efficacy and the long half-time 
of the FP-GR complex supports the practicality of using 
once-daily dosing schedules.
The systemic availability of intranasal FP is very low when 
using standard dosing regimens that the plasma   concentration 
of FP is often below the limit of detection. Using a higher 
dosing schedule of up to 12 times the normal dose and 
a more sensitive detection procedure, the mean absolute 
  bioavailability for FP intranasal drops and spray was 0.06% 
and 0.51%, respectively, of the administered dose.43 Thus the 
data related to the pharmacokinetics of intranasal FP are lim-
ited and much of the information we have is related to studies 
using either oral or intravenous   dosing regimes. Even with 
oral doses of 10 mg twice daily, the systemic   bioavailability of 
FP was less than 1%.44   Following intravenous administration 
at a dose range of 0.25 to 1 mg, FP   demonstrated extensive 
tissue distribution with a mean residence time of 4.9 hours 
and rapid tissue   clearance with the elimination half-life 
measured at 7.8 hours.45 Oral   bioavailability of FP is almost 
absent due to poor gut absorption and extensive hepatic first 
pass metabolism46 such that any systemic concentrations of 
intranasal FP will be as a result of absorption via the nasal 
mucosa. Given that a significant proportion of inhaled nasal 
steroids will be swallowed, FP will have negligible systemic 
availability and thus predictably have no bio-systemic effects. 
FP has a rapid rate of systemic clearance with oral doses of up 
to 1 to 16 mg becoming undetectable in blood 6 hours after 
administration. Intravenous administration was associated 
with clearance rates that approximated hepatic blood flow con-
sistent with extensive hepatic first pass metabolism.47 During 
hepatic metabolism, FP undergoes de-esterification with cleav-
age of the   fluromethylthioester group at the 17β position to 
the 17β-carboxylic acid.46 This inactivates the   glucocorticoid 
  molecule before its release into the systemic circulation. There 
Table  1  Summary  of  glucocorticoid  receptor  (GR)  binding 
kinetics of fluticasone propionate and fluticasone furoate relative 
to dexamethasone (Dex)42
Glucocorticoid Fluticasone  
propionate (FP)
Fluticasone  
furoate (FF)
Kd 0.51 nmol/L ± 0.03 0.3 nmol/L ± 0.02  
(Dex = 8.8 nmol ± 0.41)
RRA (GR) 1775 ± 130  2989 ± 135 
(Dex = 100 ± 5)
Systemic 
bioavailability
0.51% 
(800 μg 3 times daily)
0.5% 
(880 μg at bedtime)
Notes: values are presented as the mean and standard deviation of the mean. 
The  average systemic bioavailability of FP and FF relative to the intranasal dose 
administered is given.43,58
Abbreviations:  Kd,  equilibrium  dissociation  constant;  RRA,  relative  receptor 
affinity. Journal of Asthma and Allergy  2010: 3 submit your manuscript | www.dovepress.com
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does not appear to be any saturation of this process even at 
oral doses of 4000 μg. Oral FP is excreted   predominantly 
via the gut in the range of 87% to 100%, up to 40% as the 
17β-carboxylic acid metabolite. Less than 5% is removed in 
the urine with around 18% as the 17β-carboxylic acid.47
Therapeutic efficacy in seasonal 
allergic rhinitis
Several large, double-blind, placebo-controlled studies have 
established the clinical efficacy of FP in SAR. An initial 
dose-ranging study established that 25 μg, 100 μg and 
400 μg given on a twice-daily regime had superior clinical 
efficacy compared to placebo and this was evident as early 
as 3 days into dosing.30 Subsequent studies evaluated clinical 
efficacy and the further safety of FP. A study of adults with 
SAR in season evaluated FP aqueous nasal spray using either 
200 μg daily versus 100 μg twice daily.48 Both regimes led to 
  significant improvements in total symptom reduction with no 
significant difference between them. However, a s  ignificant 
reduction in nasal obstruction only was demonstrated for 
100 μg twice daily rather than 200 μg once daily in the 
1-study of 4 weeks’ duration.48 In the same study, only the 
100 μg twice-daily regime demonstrated a statistically sig-
nificant reduction in the use of rescue medication compared 
to placebo. A   significant proportion of individuals continue 
to have severe SAR despite intervention with intranasal ste-
roids. Given the encouraging safety profile from the earlier 
dose-ranging studies, several groups investigated whether 
doubling the doses of FP would confer any further impact 
on disease. A single-center study enrolling 90 volunteers 
with more severe SAR demonstrated that 200 μg twice daily 
versus 200 μg once daily leads to a significant improvement 
in the number of symptom free days without nasal itching 
and conjunctivitis.49 Although an important trend in the 
overall reduction of symptom scores was demonstrated here, 
significant reduction of the individual symptom score was 
seen only for nasal itch.49 In a separate study, individuals with 
severe SAR uncontrolled with 200 μg of FP once daily over 
2 weeks were then randomized to 200 μg twice daily for a 
further 2 weeks.50 This conferred a statistically significant 
advantage with increased symptom-free days in terms of 
decreased nasal congestion on waking and in the daytime. 
Although there were improvements in rhinorrhea, sneezing 
and nasal itch these were not statistically significant.
Response to treatment can also be assessed in terms of 
  rescue medication use. FP at either 100 μg twice daily or 
200 μg once a day confers a significant advantage over   placebo 
in all studies in reducing rescue medication. Although 100 μg 
twice daily appears to confer an advantage over 200 μg once 
daily in at least 2 studies,48,49 a total daily dosage higher than 
200 μg of FP does not confer any further advantage in this 
respect. FP 200 μg provided significant symptom relief in SAR 
even when used on an ‘as needed basis’.51 The pooled data from 
studies predict the onset of therapeutic effect of FP to be within 
12 hours after intranasal administration.52 Once-daily dosing 
with FP at either 100 μg or 200 μg confers similar clinical 
efficacy both superior to placebo in children 4 to 12 years of 
age and adolescents with SAR.53–55 In clinical practice, FP is 
prescribed at 100 μg into each nostril once a day, which is an 
effective dose for most individuals with AR. With more severe 
disease, particularly nasal congestion, it is common practice to 
use a twice-daily regime with 200 μg until control is achieved. 
It is safe to use higher doses of up to 400 μg, the standard 
dose per unit contained with FP nasule (drop) preparations in 
individuals with severe disease.56 The bioavailability of the 
intranasal drops formula is estimated to be 8 times lower than 
the equivalent dose of the nasal spray formulation.43
Fluticasone furoate
Fluticasone furoate is a new topical corticosteroid with a 
licence for the treatment of both seasonal and perennial 
AR. It is delivered as a well-dispersed mist composed of 
fine   droplets of particles 20 to 50 μm in diameter,   probably 
  leading to an even area of distribution over the nasal   mucosa.57 
FF is a trifluorinated molecule that is similar in structure to FP 
other than the addition of a furoate ester to the 17α-OH group 
(Figure 1B). In FP, this location is e  sterified with propionic 
acid (Figure 1B). Given the   structural homology, one would 
predict a similar pharmacokinetic and   pharmacodynamic 
  profile and therapeutic efficacy of FF to FP. In fact, the 
emerging evidence suggests that FF may have a superior 
product profile and enhanced clinical efficacy in AR.57
As with FP, FF demonstrates a high lipophilicity with a 
remarkably fast association with the glucocorticoid receptor 
and a subsequently slow dissociation rate. The propensity of the 
GC-GR to dissociate, expressed as the Kd, is 0.3 nmol/L for FF. 
For comparision the Kd of dexamethasone was 8.8 nmol/L, Kd 
of FP 0.51 nmol/L and the Kd of mometasone furoate (MF) 
0.41 nmol/L in this particular set of experiments (Table 1).42 The 
relative receptor affinity (RRA) of FF to the GR has been shown 
to be 2989, compared to   dexamethasone with an RRA at 100, 
and with FP and MF at 1775 and 2244 respectively.42 The differ-
ence in the RRA between FF and FP reflects the potent effects 
of ester-furoylation at the 17α-OH location. The 17α-furoate 
ester substitute allows the FF molecule to fully occupy the GR 
17α-pocket. Such molecular intimacy will allow   additional  Journal of Asthma and Allergy  2010: 3 submit your manuscript | www.dovepress.com
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structures of the   fluticasone core to further interact with the 
receptor. In vitro data   demonstrate enhanced activity of FF for 
the GR with potent activation of the glucocorticoid response 
  element pathway along with repression of NF-κB induction of 
t  ranscriptional events. Almost complete abolition of eosinophil 
influx into the airway in an animal model of allergic inflam-
mation could be demonstrated with an intratracheal FF dose 
of only 30 μg.57 Detection of plasma FF following intranasal 
dosing was again below the level of detection with even up to 
doses of 880 μg per day and the a  verage absolute bioavailability 
  following intranasal administration was only 0.5%.58 As with FP, 
extensive hepatic first pass metabolism of FF via the   cytochrome 
P450 3A4 enzyme system limits oral bioavailability.46,59 Thus 
FF presents an impressive   pharmacodynamic profile compared 
to the other new   generation glucocorticoids. Rapid high a  ffinity 
binding along with   prolonged tissue retention, and minimal 
systemic availability markets FF is an attractive option for 
topical therapy.
Seasonal allergic rhinitis
Four double-blind placebo-controlled studies have been 
  conducted on FF in adults and children over 12 years of age 
with SAR. One was a dose ranging study to evaluate the effi-
cacy and safety of FF at 55 μg, 110 μg, 220 μg and 440 μg once 
daily in the US mountain cedar pollen season.60 Although all 
doses other than 55 μg demonstrated similar clinical efficacy 
that was statistically significant compared to placebo, it was the 
110 μg dose that was thought to offer the optimal therapeutic 
ratio and was chosen for further   clinical evaluation. Three 
phase III studies assessed the clinical efficacy and safety of 
once daily FF at 110 μg at the height of season for European 
grass pollen, US ragweed and US mountain cedar.61,62,63 In total 
1142 volunteers with SAR were randomized to either 110 μg 
of FF (n = 571) or placebo (n = 570) in season. Summated data 
from these studies confirmed the onset of efficacy of FF to be 
within 24 hours of the initial dosing. Each study demonstrated 
  significant improvement in clinical parameters assessed related 
to nasal and ocular symptoms. As well as improvement in the 
reflective total nasal symptom scores (rTNSS), there was also 
significant improvement in the instantaneous iTNSS (iTNSS) 
recorded each day just prior to dose administration. This 
confirmed that a once-daily dosing is efficacious for the entire 
24-hour period. Currently the recommended starting dose of 
FF in adults and children over 12 years of age is 110 μg daily 
per nostril, with the aim of reducing to 55 μg once daily once 
symptom control has been achieved.
An impressive finding from these studies was the 
  consistent efficacy of FF treatment on reducing ocular 
  manifestations in SAR. Symptom reduction was associated 
with increased positive scoring in the rhinoconjunctivitis 
quality of life questionnaire (RQLQ). Ocular symptoms 
of allergy can be particularly troublesome for the patient, 
are often difficult to treat and therefore represent an unmet 
  clinical need. Although other INS demonstrate some effect 
on the ocular symptoms of SAR, this efficacy has not always 
been reproducible.64 Studies with FF demonstrate   consistency 
and reproducibility in reduction of ocular   symptoms.64 
It is   presumed the effect of intranasal steroids on eye 
  manifestations of allergy is related to the effects of decreased 
inflammatory mediators that prime nasal neurogenic tissue 
and initiate the nasal – ocular reflex.11,65 The high affinity 
of FF for the glucocorticoid receptor and slow dissociation 
rate probably give FF superiority in terms of attenuation of 
inflammation,66 which may reduce neuronal activation.67
The experience of FF for SAR in children is limited at 
present to a single study of either 55 μg or 110 μg once daily 
versus placebo in 554 children aged between 2 and 11 years 
of age over 2 weeks.68 Clinical efficacy was most evident 
only at the 110 μg dose. Despite these findings caution is still 
advised with children and the recommended starting dose of 
FF for children 2 to 11 years of age is 55 μg per daily dose, 
increasing to 110 μg daily only for non-responders or during 
exacerbation periods.
Safety and adverse events
The term steroid is associated with apprehension of adverse 
s  ystemic effects by both clinicians and patients. In particular, con-
cerns over effects on hypothalamic – pituitary –   adrenal (HPA) 
suppression, bone growth and density, posterior   sub-capsular 
cataract formation and raised ocular pressure   associated with 
systemic administration of steroids have often been incorrectly 
extrapolated to locally delivered   steroids, regardless of specific 
formulation, dosage and site of   administration. This has led to 
poor adherence and   treatment failure.69 Generally, studies in 
children and adults have   consistently failed to demonstrate any 
clinically significant effect on the HPA-axis,70 bone growth 
or cataract formation/glaucoma. This is a reflection of low 
systemic   bioavailability following intranasal administration. 
Clinical guidelines provide reassurance.17 The high therapeutic 
index of both FP and FF predicted by the key pharmacological 
properties has been borne out by the detailed clinical safety 
studies of these products.
Safety of FP was established early on. In the initial 
  dose-ranging study, even with the highest dose of 400 μg 
twice-daily there were no increased side effects versus 
  placebo for FP.30 Although only a 2-week dosing period was  Journal of Asthma and Allergy  2010: 3 submit your manuscript | www.dovepress.com
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used, no HPA axis effects were demonstrated. The safety 
and tolerance of FP in doses of 50 μg, 200 μg or 800 μg 
twice daily over a 4-week period in patients with SAR con-
firmed that even at the highest total dose of 1600 μg there 
were no increased adverse events compared to placebo.71 
Detailed evaluation of adrenal function in terms of early 
morning and ACTH-stimulated cortisol and 24-hour urinary 
  cortisol   excretion demonstrated no effect of FP. Several other 
  studies using higher than standard doses of FP have failed to 
  demonstrate HPA-axis effects.72,73 Studies assessing adverse 
effects on other body systems are limited. A 12-month study 
with FP with 200 μg daily did not demonstrate any effect 
on bone density or occurrence of cataract or glaucoma.74 
A similar open year-long study of 200 μg daily showed no ill 
effects on the nasal mucosa, in fact saccharin clearance was 
improved following therapy.75 Overall there was no increased 
severity or frequency of adverse events with FP compared to 
placebo. The pediatric studies were similarly encouraging. 
Several studies in children 4 to 11 years of age or adolescents 
12 to 17 years of age with FP at 100 or 200 μg per day over 
2 to 12 weeks failed to show any HPA-axis effect or any 
increased adverse effect compared to placebo.76,77
With FF, the dosing study with up to 440 μg once daily for 
2 weeks in adults with SAR failed to show any effect on HPA 
function.60 A study of longer duration in adults and adolescents 
with perennial allergic rhinitis also confirmed the long term 
safety of FF.78 Detailed evaluation of FF in children in children 
2 to 11 years of age at 110 μg daily for 6 weeks,79 2 weeks68 
and 12 weeks80 all confirmed an absence of any effect on HPA 
function.81 Effect on bone growth is of particular concern in 
children. FP at 110 μg per day over 2 weeks had no effect 
on lower leg growth in a 6- to 12-year group over a 2-week 
period.82 Further studies of longer duration are still needed but 
the safety data of FF in children is encouraging. The European 
Medicines Agency (EMEA) has granted the licence for the 
use of FF (Avamys®; GlaxoSmithKline) for adults, adoles-
cents from 12 years upward and children from 6 to 11 years 
only. The US Food and Drug Administration (FDA) agency, 
however, has improved FF (Veramyst®; GlaxoSmithKline) 
for children from 2 years upwards.
Tolerability and compliance
No product will have any impact on disease unless the 
patient group uses it correctly. Tolerability of the product 
and concordance with therapy is determined to some extent 
by the ease of delivery, the sensory attributes of the   product 
such as taste along with the convenience of once-daily use 
and the absence of any adverse events.83–85 Ease of any 
delivery device is dictated by the absence of any complicated 
priming procedure prior to use. Delivery of a set drug dose 
independent of the pressure or speed applied by the patient 
to the device is particularly relevant to a pediatric and elderly 
population. Clear indication of the remaining amount of 
available drug in the apparatus simplifies self-management.86 
Comfort during administration is also important and local 
adverse events that arise from mechanical nasal irritation 
such as anterior nasal crusting and bleeding are particularly 
  bothersome, and reported to affect up to 20% of individuals 
leading to cessation of therapy.87 The association of systemic 
and dermatological topical steroids with direct connective 
  tissue atrophy has often been incorrectly extrapolated as 
casual for nasal crusting and bleeding in the nasal mucosa88 
and has led to patients and on occasions physicians to 
  discontinue treatment. Advice regarding administration to 
the outer aspect of the nasal lining using two different sites 
for the two actuations, in order to maximize the area of 
mucosal contact and avoid septal deposition, is important. 
A reminder not to sniff the drug back heartily, thus removing 
it too quickly from nose to the posterior pharynx, should also 
be given. The drug delivery device and vehicle are therefore 
essential aspects to consider when prescribing an INS.
Patient preference in regard to specific sensory attributes of 
a drug may be determinant of adherence to therapy.   Important 
sensory attributes include minimal odor and irritant effect, 
absent taste and product moistness. It has been shown that the 
intensity of such sensory components is inversely   correlated 
with preference.84 Sensory attributes vary   considerably 
between current market preparations.84,85,89 For example 
triamcinolone acetonide (TAA) demonstrates less odor and 
taste with no local irritation and has been shown to have a 
sensory advantage over FP and MF in studies.89,90 However, 
the pharmacokinetic and pharmacodynamic characteristics of 
TAA would not favor first-line intranasal use.91
The established INS are currently delivered using a basic 
mechanical pump system that delivers a jet or squirt of drug. 
However, they differ considerably in terms of exact priming 
procedure, nozzle size and the ability to hit the nasal mucosa 
without change in head posture. Much of the focus with 
these products has been with clinical efficacy of the drug, 
  without too much attention to the importance of device design 
in   relation to factors that ensure compliance and patient 
  acceptance. Understanding the importance of the delivery 
device relative to features that ensure compliance with 
therapy has led to extensive investment in the design of the 
delivery device for the newest product FF. The system for FF 
has an innovative design that is a prime-free device, allows  Journal of Asthma and Allergy  2010: 3 submit your manuscript | www.dovepress.com
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easy grip with a side actuation mechanism such that the user’s 
fingers are away from the delivery nozzle when activating 
the spray.92 Abolishing the need for fingers on the nozzle 
base allow the use of a shorter delivery nozzle, making the 
device less invasive. Nasal pain, bleeding and crusting from 
mechanical irritation are important   aggravating factors for 
patients and a less penetrative device may be better   tolerated, 
particularly by children. Parents can more effectively 
  administer the spray to children using a   minimum actuation 
force. The   formulation is alcohol free and hence there is less 
nasal burning and irritation on mucosal deposition.
Conclusion
Both FP and FF are excellent examples of how an   understanding 
of molecular structure – function   relationships can be used to 
achieve good clinical efficacy without   compromising safety. 
FP is a long established intervention for AR with an excellent 
therapeutic index. FF represents an advance not simply in how 
sophisticated molecular modification can further improve 
pharmacological profile, but also shows the importance of 
focus on factors that may improve patient tolerability and 
hence compliance. Such focus should further advance thera-
peutic intervention for patients with AR.
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